Grant ID RP130020
Awarded On December 05, 2012
Title Investigating PI3K inhibition-mediated feedback regulation in renal cancer treatment
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Boyi Gan
Cancer Sites Kidney and Renal Pelvis, Other
Contracted Amount $826,196
Lay Summary

How to choose the most effective targeted cancer therapy strategy for individual cancer patient is an important and challenging issue. Single-agent therapy usually targets one particular molecule or pathway; however, such therapy often activates other cancer signaling pathways, resulting in drug resistance over time. A more effective therapy may therefore require a combination of agents to inhibit the other cancer signaling pathways that are activated by a particular drug. However, combination therapies generally involve problems with toxicity. Also, only a fraction of cancer patients typically benefit from combination therapies, which means many other patients who receive these therapies do...

Read More